Brain Neoplasm Clinical Trial
Official title:
Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery
Several modalities have been studied to prevent coughing during emergence, including extubation in a deep plane of anesthesia but have proved to be unreliable. So far, no reliable method is recommended as standard of care. The advantages of administering tramadol includes a long duration of action, rapid recovery, limited depression of respiratory function and no effect on platelet makes it a safe medication to use for neurosurgical patients after craniotomy. The primary objective of the study is to observe the effect of single dose of tramadol (1mg/kg) administered 45 minutes before extubation on hemodynamic response (measurement of B.P and H.R) during extubation.
Extubation after intracranial tumor surgery is desirable in order to make an early diagnosis
of intracranial complications. Extubation however, may be associated with haemodynamic and
metabolic changes e.g. agitation, increased oxygen consumption, catecholamine secretion,
hypercapnia and systemic hypertension.
These changes cause cerebral hyperemia, intracranial hypertension leading to cerebral oedema
or haemorrhage, thus it is important to have smooth extubation with minimal haemodynamic and
metabolic effects.
Incidence of coughing on emergence from general anesthesia ranges from 38% to 96%. This may
also result in postoperative intracranial hemorrhage, intracranial hypertension, cerebral
edema or intraocular hypertension.This can be detrimental in neurosurgery.
Several modalities have been studied to prevent coughing during emergence, including
extubation in a deep plane of anesthesia but have proved to be unreliable. So far, no
reliable method is recommended as standard of care.
Tramadol, a synthetic opioid of the aminocyclohexanes group, is a centrally acting opioid
analgesic that is used to treat moderate-to-severe pain and has an inhibitory effect on M1
and M3 muscarinic receptors. It also reduces the incidence of cough and improves extubation
quality, and provides more stable haemodynamics during emergence. It neither causes
respiratory depression, nor affects intracranial pressure (ICP) and cerebral perfusion
pressure (CPP). Other potential advantage of administering tramadol includes a long duration
of action, rapid recovery, limited depression of respiratory function and no effect on
platelets thus making it a safe medication to use for neurosurgical patients after
craniotomy. The onset of effect following a single dose is 3 to 5 minutes with peak effect at
45 minutes.
Aim of doing this study is to observe the effect of a single dose of tramadol on quality of
tracheal extubation as judged by incidence of coughing and haemodynamic changes at emergence
from anesthesia.
OBJECTIVE:
Primary Objective: To observe the effect of single dose of tramadol (1mg/kg) administered 45
minutes before extubation on haemodynamic response (measurement of B.P and H.R) during
extubation.
Secondary Objective: To measure the quality of emergence from general anaesthesia by
measuring the frequency of cough, laryngospasm and episodes of desaturation.
OPERATIONAL DEFINITION:
Emergence Period: This will be defined as the time from the recovery of spontaneous breathing
after giving reversal to tracheal extubation.
Quality of emergence: Good quality emergence will be defined as extubation not associated
with coughing, bucking, tachycardia, hypertension, laryngospasm or bronchospasm.
Tachycardia and hypertension: Rise in heart rate and blood pressure more than 20% from
baseline value.
Extubation response: Physiological response related to blood pressure and heart rate during
extubation of trachea is called extubation response,
HYPOTHESIS:
Tramadol obtunds haemodynamic and cough response to extubation and thus results in good
quality emergence after supratentorial craniotomy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001972 -
PET Scan of Brain Metabolism in Relation to Age and Disease
|
N/A | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Withdrawn |
NCT03234309 -
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00178295 -
Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury
|
N/A | |
Recruiting |
NCT04810871 -
Surgical Resection of Latent Brain Tumors Prior to Recurrence
|
N/A | |
Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00040573 -
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04553757 -
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
|
||
Recruiting |
NCT02754544 -
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
|
N/A | |
Recruiting |
NCT03216148 -
18F-FET PET in Childhood Brain Tumours
|
Phase 2 | |
Completed |
NCT00001171 -
Evaluation of Factors in Human Brain Tumors
|
N/A | |
Withdrawn |
NCT01413438 -
Bevacizumab With or Without Surgery for Adult Glioblastomas
|
Phase 2 | |
Not yet recruiting |
NCT05516485 -
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
|
N/A | |
Recruiting |
NCT02639325 -
Tumor Related Epilepsy
|
||
Recruiting |
NCT02672995 -
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
|
Phase 1 |